• A Hybrid Conference and Internet Event
• Sponsored by the Pharmaceutical Compliance Forum
• May 14 - 16, 2012
• Onsite at the Hilton Budapest, Budapest, Hungary
• Online In Your Own Office or Home live via the Internet with 24/7 Access for Six Months
• www.InternationalPharmaCongress.com

PRESS RELEASE
Phone: 800-503-8171
Email: registration@hcconferences.com
Website: www.InternationalPharmaCongress.com

WASHINGTON DC USA -- PHARMA UPDATE NEWS SERVICE™ -- APRIL 18, 2012: The International Pharmaceutical Compliance Congress, www.InternationalPharmaCongress.com, will take place on May 14 - 16, 2012 at the Hilton Budapest in Budapest, Hungary. The Congress will be offered both onsite and live and archived for 6 months over the Internet.

KEYNOTE SPEAKER Christopher A. Viehbacher Chief Executive Officer, Sanofi, Paris, France

FEATURED SESSIONS International Pharma Congress Vision and Overview The Role of Global Compliance in the Pharmaceutical Enterprise EU Annual Compliance and EFPIA Compliance Initiatives Update CEE Annual Compliance Update MEA Annual Compliance Update Regional Anti-Bribery Developments Roundtable: US FCPA, UK Bribery Act, Russian Anti-Bribery Act, OECD Anti-Bribery Convention E4ethics Congresses European Assessment Platform Regional Transparency and Disclosure Initiatives: UK, US, Netherlands, France, Slovak Republic Global Transparency Management: Industry Survey Key Findings Regional Compliance Code Update Roundtable: IFPMA, EFPIA, EUCOMED, MEA, Russia, Turkey, PhRMA Third-party Intermediaries: Due Diligence and Monitoring Considerations Business Ethics and Reputation in the Pharmaceutical and Medical Device Enterprises

PHARMA COMPLIANCE TRACKS Central and Eastern Europe Compliance Update Middle East and Africa Compliance Update Israel Compliance Update Global Anti-Bribery Update Global Compliance Audits and Monitoring Global Transparency, Discourse and Aggregate Spend New EU Provisions Governing Compliance with Pharmaceutical Regulatory Laws The Italian Regulatory and Compliance Scene in Depth: A Case Study Asia Pacific Regulatory and Compliance Scene in Depth: A Case Study Lessons with Global Compliance Issues and Initiatives in the Medial Device Sector

OTHER KEYNOTE FACULTY Bulent Becan Managing Partner, Atuva Management Consultancy and Trade Ltd.; Consultant in Ethics Issues, Turkish Research Based Pharmaceutical Companies Association (AIFD), Istanbul, Turkey Richard Bergström Director General, European Federation of the Pharmaceutical Industries and Associations (EFPIA), Former Director General, LIF Sweden, Brussels, Belgium Joe Henein President and Chief Executive Officer, NewBridge Pharmaceuticals; Former Regional Managing Director, Middle East and North Africa, Wyeth Pharmaceuticals, Dubai, United Arab Emirates Jose F. Zamarriego Izquierdo Director Unidad de Supervision Deontologica, FARMAINDUSTRIA, Madrid, Spain Andrew Jack Pharmaceuticals Correspondent, Financial Times, London, UK Aline Lautenberg Senior Legal Counsel, Eucomed, Brussels, Belgium Bernard Maillet, MD Member, Flemish Chamber of the Board for Specialists for Pathology, Treasurer, VBS-GBS, Member, EUCOMED's Compliance Panel, Former Secretary General, UEMS and EACCME, Antwerp, Belgium Tamara Music Manager, Influenza Vaccines & Code Compliance, IFPMA, Geneva, Switzerland Marie-Claire Pickaert Deputy Director General, European Federation of Pharmaceutical Industries and Associations (EFPIA), Brussels, Belgium Andy Powrie-Smith Director for Trust and Reputation, Association of the British Pharmaceutical Industry (ABPI), London, UK Heather Simmonds Director, Prescription Medicines Code of Practice Authority, London, UK Sona Strachotova, MBA Executive Director, Slovak Association of Research-based Pharmaceutical Companies (SAF), Bratislava, Slovak Republic Madina Torchinova, Esq. Regional Compliance Officer CEE, Sandoz; Former Director Legal and Regulatory Affairs, Association of International Pharmaceutical Manufacturers (AIPM), Russia, Munich, Germany Matthijs M. van Blokland, Esq. General Counsel, Prosensa, General Counsel and Senior Policy Advisor Legal Affairs, Association Innovative Medicines Nefarma, Board Member, Stichting CGRz, Amsterdam, The Netherlands

ANTICORRUPTION UPDATE: FCPA UK BRIBERY ACT, RUSSIAN ANTI-BRIBERY, OECD ANTI-BRIBERY CONVENTION Ted Acosta, Esq. Principal, Ernst & Young LLP; Former Senior Counsel, Office of Inspector General, US Department of Health and Human Services, New York, NY, USA and Paris, France John T. Bentivoglio, Esq. Partner, Skadden Arps LLP; Former Special Counsel for Healthcare Fraud and Chief Privacy Officer, US Department of Justice, Washington, DC Michael J.J. Brueck, LLM, Ph.D. (Dr. iur.) Counsel, Sidley Austin LLP, Professor of Law, German Graduate School of Management and Law, Heilbronn, Germany, Frankfurt, Germany Raymond Emson, Esq. Policy Lawyer, Serious Fraud Office, London, UK Gary F. Giampetruzzi, Esq. Vice President and Assistant General Counsel, Head of Government Investigations, Pfizer Inc., New York, NY, USA Edward F. Hanover, III General Counsel, Novo Nordisk Region International Operations A/S, Zurich, Switzerland Rosanne M. Kay, Esq. Partner, Reed Smith, London, UK Paul J. Melling, Esq. Founding Partner, Baker & McKenzie - CIS, Limited, Moscow, Russia Vivian Robinson, Esq. Partner, McGuireWoods; Former General Counsel of the UK Serious Fraud Office; Former Head, QEB Hollis Whiteman Chambers; Recorder of the Crown Court and Treasurer of Inner Temple, London, UK Joseph B. Tompkins, Jr. Partner, Sidley Austin LLP; Former Deputy Chief of the Fraud Section, Criminal Division, United States Department of Justice, Washington, DC, USA GLOBAL TRANSPARENCY, DISCLOSURE AND AGGREGATE SPEND Ronny Arijs Vice President Global Sustainability and Chief Compliance Officer, Grunenthal; Member, EFPIA Compliance Workgroup; Former Senior Compliance Manager, GE Healthcare, Brussels, Belgium Yogesh Bahl, MBA Partner, National Practice Leader - Life Sciences, Deloitte Financial Advisory Services LLP, New York, NY, USA Michael Bartke, PhD Director, Compliance Management, Internal Audit and Corporate Compliance, Daiichi Sanky Europe GmbH, Vice Chair, EFPIA Compliance Committee, Munich, Germany Julie Bonhomme, Esq. Legal Manager, LEEM, Paris, France William E. Buzzeo, MS Vice President and General Manager, Global Compliance Solutions, Cegedim Relationship Management, Richmond, VA, USA Fred Eaton Partner, Polaris Management Partners, New York, NY, USA Kelly B. Freeman, PhD Ethics and Compliance Officer, Eli Lilly and Company, Indianapolis, IN, USA Jonathon Kellerman Principal, Pharmaceutical and Life Sciences Advisory Services, PricewaterhouseCoopers LLP, Florham Park, NJ, USA Keith M. Korenchuk, JD, MPH Partner, Arnold & Porter LLP, Washington, DC, USA John Patrick Oroho, Esq. Executive Vice President, Porzio Pharmaceutical Services; Principal, Porzio Bromberg & Newman PC, Morristown, NJ, USA David Wysocky Director, Pharmaceutical and Life Sciences Advisory Services, PricewaterhouseCoopers LLP, Boston, MA, USA REGIONAL COMPLIANCE CODE UPDATE: IFPMA, EFPIA, EUCOMED, MEA, RUSSIA, TURKEY Peter Dieners, Esq. Partner, Clifford Chance, Düsseldorf, Germany Michael K. Loucks, Esq. Partner, Skadden Arps LLP; Former Acting United States Attorney, US Attorney's Office for the District of Massachusetts, Boston, MA, USA BUSINESS ETHICS AND REPUTATION Andy Powrie-Smith Director for Trust and Reputation, Association of the British Pharmaceutical Industry (ABPI), London, UK Paul B. Woods, BPharm, MA, MRPharmS Independent Consultant; Former Global Compliance Policy Director, AstraZeneca, Macclesfield, Cheshire, UK CENTRAL AND EASTERN EUROPEAN COMPLIANCE UPDATE Rozalia Gyulai Regulatory Manager, Pfizer, Budapest, Hungary Tomasz Kruk, LL M, MBA Director Global Ethics and Compliance, Actavis, Zug, Switzerland Paul J. Melling, Esq. Founding Partner, Baker & McKenzie - CIS, Limited, Moscow, Russia Mariusz Witalis Partner, Fraud Investigation and Dispute Services, Ernst & Young LLP, Warsaw, Poland ISRAEL COMPLIANCE UPDATE Daniel Kessler Principal, ITR Group, Former Chief Counsel, Int'l Trade Controls, Pfizer, Former Chief Counsel, Int'l Trade Controls, Wyeth, Tel Aviv, Israel Guy Schmidt, MBA Compliance Director, AstraZeneca (Israel) Ltd., Tel Aviv, Israel MIDDLE EAST/AFRICA COMPLIANCE UPDATE Hulya Baran Director, Ethics & Compliance TMEA - CIS, Eli Lilly and Company, Istanbul, Turkey Sameh Farag Associate Vice President Global Compliance, Intercontinental Zone Global Compliance, Sanofi, Paris, France Meltem Ozker Gunduz Regional Legal Counsel and Compliance Officer, Business Area Near East, Novo Nordisk, Istanbul, Turkey Liz MacGillivray Compliance Director, Corporate Integrity and Compliance, Novartis International AG, Basel, Switzerland Laura Nassar Regional Pharma HCC Officer Emerging Markets, Johnson & Johnson, Beirut, Lebanon GLOBAL COMPLIANCE AUDITING AND MONITORING BEST PRACTICES Antoinette Gutierrez-Crespin Partner, Ernst & Young, Paris France Stefan Heissner Managing Partner, Fraud Investigation and Dispute Services, Ernst & Young GmbH, Düsseldorf, Germany Luca M. Liberatore Director Large European Affiliates and CEE, Amgen International HealthCare Compliance, Milan, Italy Michael J. Morgan Ethics and Compliance Officer, Australia, Canada and Europe, Eli Lilly and Company, Windlesham, Surrey, United Kingdom Dave O'Shaughnessy Vice President, Global Compliance, Astra-Zeneca; Former Vice President and Compliance Officer, Emerging Markets and Asia Pacific, GlaxoSmithKline, London, UK L. Stephan Vincze, JD, LL M, MBA National Managing Director, Life Sciences/Forensic and Dispute Services, Deloitte Financial Advisory Services, LLP, Boston, MA, USA DUE DILIGENCE AND MONITORING THIRD PARTY INTERMEDIARIES John Alexander Head of European Compliance, Mundipharma International, Former EMEA Director of Compliance, Ortho Clinical Diagnostics, Ormer Healthcare Compliance Officer, Janssen-Cilag, Cambridge, United Kingdom Karl Boonen, Esq. Senior Director Business Practices and Compliance EMEA and Canada, Johnson & Johnson, Antwerp, Belgium Nieves Liste, MBA Global Business Compliance Director, Covidien, Barcelona, Spain Marc L. Miller Partner, KPMG LLP, New York, NY, USA NEW EU PROVISIONS GOVERNING COMPLIANCE WITH PHARMACEUTICAL REGULATORY LAWS Sue Egan Director and Principal Consultant, Sue Egan Associates; Editor, Life Science Compliance; Former Vice President Compliance, AstraZeneca, Great Missenden, Buckinghamshire, UK Evelyn Lemaire Director, PricewaterhouseCoopers LLP, Zurich, Switzerland Maurits J.F. Lugard, MA, JD, LL M Partner, Sidley Austin LLP; Former Member of the European Commission's Legal Service, Brussels, Belgium Paul B. Woods, BPharm, MA, MRPharmS Independent Consultant; Former Global Compliance Policy Director, AstraZeneca, Macclesfield, Cheshire, UK Elisabethann Wright, Esq. Partner, Hogan Lovells; Former Senior Legal Officer and Hearing Officer, EFTA Surveillance Authority, Brussels, Belgium THE ITALIAN REGULATORY AND COMPLIANCE SCENE IN DEPTH Maurizio Arena, Esq., Criminal Lawyer, President and Founding Member, Osservatorio 231 Farmaceutiche, Rome, Italy Maurizio Bortoletti Colonel, Carabinieri Corps, Extraordinary Commissioner, Public Healthcare Company, Salerno, Italy Maria Teresa Brassiolo President and Founding Member, Transparency International Italia, Milan, Italy Antonio Cavallaro Compliance & Internal Auditing Senior Manager, Takeda Italia Farmaceutici, Rome, Italy Edoardo Lazzarini, PhD European Compliance Officer, Biomet Italia, Milan, Italy Giuseppe Palmieri Chief Compliance Officer, Head of Risk & Compliance Management and Internal Audit, Boehringer Ingelheim Italia, Milan, Italy THE CHINESE REGULATORY AND COMPLIANCE SCENE IN DEPTH Erinn Hutchinson Director, PricewaterhouseCoopers LLP, Philadelphia, PA, USA Yuet-Ming Tham, Esq. Partner, Sidley Austin LLP, Former Regional Compliance Director, Legal Division, Corporate Compliance, Pfizer Inc., Hong Kong George Ng, Esq. Partner, Snell & Wilmer; Former Head of Legal, Chief Compliance Officer, Chief IP Counsel, Spectrum Pharmaceuticals, Inc.; Former Manager, Intellectual Property, Alpharma Inc., Costa Mesa, CA John Auerbach, MA Partner, Fraud Investigation and Dispute Services, Ernst & Young China, Shanghai, China GLOBAL MEDICAL DEVICE SECTOR COMPLIANCE ISSUES Brian Riewerts Partner, Global Pharmaceuticals and Life Sciences, PricewaterhouseCoopers LLP, Baltimore, MD, USA Sujata T. Dayal, Esq. Corporate Vice President and Chief Compliance Officer, Biomet; Former Counsel, Domestic Legal Operations, Abbott Laboratories; Former Member, PCF Executive Committee, Warsaw, IN, USA Peter V. Rother, Esq. Associate General Counsel and Senior Compliance Director, Cardiovascular Division, St. Jude Medical, Plymouth, MN, USA Tamara Tubin Director Ethics and Compliance International, CareFusion International, Former Associate Director Compliance EMEA, ZIMMER GmbH, Zürich, Switzerland

	This site complies with the HONcode standard for trustworthy health information: verify here.

The Pharmaceutical Compliance Forum (PCF) is a coalition of senior compliance professionals and legal counsel from more than 50 of the largest research-based pharmaceutical manufacturers. The PCF was founded in early-1999 by compliance professionals from the pharmaceutical industry to promote effective corporate compliance programs. The members meet twice a year, for two days, focusing on open and informal sharing of compliance information, best practices, and current developments in the field, and sponsors a two-day international compliance congress in the Spring and a three-day US compliance congress each Fall.